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Abstract: A variety of factors have been identified
that regulate angiogenesis, including the CXC che-
mokine family. The CXC chemokines are a unique
family of cytokines for their ability to behave in a
disparate manner in the regulation of angiogenesis.
CXC chemokines have four highly conserved cys-
teine amino acid residues, with the first two cys-
teine amino acid residues separated by one non-
conserved amino acid residue (i.e., CXC). A second
structural domain within this family determines
their angiogenic potential. The NH2 terminus of
the majority of the CXC chemokines contains three
amino acid residues (Glu-Leu-Arg: the ELR motif),
which precedes the first cysteine amino acid resi-
due of the primary structure of these cytokines.
Members that contain the ELR motif (ELR1) are
potent promoters of angiogenesis. In contrast,
members that are inducible by interferons and lack
the ELR motif (ELR2) are potent inhibitors of
angiogenesis. This difference in angiogenic activity
may impact on the pathogenesis of a variety of
disorders. J. Leukoc. Biol. 68: 1–8; 2000.
Key Words: cytokines z neovascularization z wound repair z tumor-
igenesis z tumor metastasis
INTRODUCTION
Angiogenesis is the formation of new blood vessels from pre-
existing microvasculature. Angiogenesis is a biological process
that is critical to both physiological and pathological processes
[1–11]. The regulation of angiogenesis depends on a dual, yet
opposing balance of angiogenic and angiostatic factors that
promote or inhibit neovascularization, respectively. For exam-
ple, under homeostatic conditions the rate of normal capillary
endothelial cell turnover is measured in months or years [12,
13], suggesting a balance in the biological effect of angiogenic
and angiostatic factors. During wound repair the formation of
granulation tissue is associated with a shift in the balance
favoring the predominance of angiogenic factors that supports
the development of new functioning capillaries within days [8].
In contrast, the latter phases of wound repair are associated
with a marked decline of angiogenesis. This event correlates
with the involution of granulation tissue that is concomitant
with re-epithelialization. These events suggest that angiogen-
esis of wound repair is tightly controlled and temporally related
to the imbalance of expression of angiogenic and angiostatic
factors that ultimately regulates angiogenesis. The temporal
imbalance in angiogenic and angiostatic factors in granulation
tissue can either represent a marked reduction in the elabora-
tion of angiogenic factors and/or a simultaneous increase in
factors that inhibit neovascularization [14]. In contrast to the
precise regulation of angiogenesis in wound repair, aberrant
angiogenesis can lead to an imbalance in the relationship of
angiogenic and angiostatic factors that favors persistent angio-
genesis. This type of environment can contribute to the patho-
genesis of tumor growth and metastases, and the promotion of
chronic fibroproliferative disorders. The complement of angio-
genic and angiostatic factors may vary among different physi-
ological and pathological settings. However, the recognition of
this dual mechanism of control is critical in order to gain
insight into this complex process and understand aberrant
angiogenesis associated with a variety of pathological condi-
tions. The CXC chemokines are a unique family of cytokines
that can regulate angiogenesis in a disparate manner and will
be the subject of this review.
CXC CHEMOKINES, CXC CHEMOKINE
RECEPTORS, AND ANGIOGENESIS
CXC chemokines are characteristically heparin binding pro-
teins. On a structural level, they have four highly conserved
cysteine amino acid residues, with the first two cysteines
separated by one nonconserved amino acid residue [15–27].
Although the CXC motif distinguishes this family from other
chemokine families, a second structural domain dictates their
angiogenic activity. The NH2 terminus of the majority of the
CXC chemokines contain a three-amino-acid motif (Glu-Leu-
Arg: the ELR motif), which precedes the first cysteine amino
acid of the primary structure of these cytokines [15–27]. The
family members that contain the ELR motif (ELR1) are potent
promoters of angiogenesis [23] (Table 1). In contrast, members
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that are induced by interferons and lack the ELR motif (ELR2)
are potent inhibitors of angiogenesis [23, 28–30] (Table 1).
Therefore, on a structural/functional level, members of the
CXC chemokine family can either promote or inhibit angio-
genesis, and the imbalance of the local expression of these
chemokines may be important in the regulation of angiogenesis
under both physiological and pathological conditions.
Angiogenic (ELR1) CXC chemokines
Members of the CXC chemokine family that behave as angio-
genic factors include interleukin-8 (IL-8), epithelial neutrophil
activating protein-78 (ENA-78), growth-related genes (GRO-a,
-b, and -g), granulocyte chemotactic protein-2 (GCP-2), and
NH2-terminal truncated forms of platelet basic protein (PBP),
which include connective tissue activating protein-III (CTAP-
III), beta-thromboglobulin (b-TG), and neutrophil activating
protein-2 (NAP-2) [23, 31–33] (Table 1). ELR1 CXC chemo-
kines directly induce endothelial cell chemotactic and prolif-
erative activity in vitro, and angiogenesis in vivo in the absence
of preceding inflammation [23, 32–35]. Their angiogenic ac-
tivity is distinct from their ability to induce inflammation.
Although a specific CXC chemokine receptor(s) that medi-
ates the angiogenic activity of these cytokines remains to be
determined, the candidate CXC chemokine receptors for this
effect are CXCR1 and/or CXCR2. Only IL-8 and GCP-2 spe-
cifically bind to CXCR1, whereas all ELR1 CXC chemokines
bind to CXCR2 [15–27]. The ability of ELR1 CXC chemokine
ligands to bind to CXCR2 supports the notion that this repre-
sents the receptor for the mediation of angiogenic activity by
ELR1 CXC chemokines. This is further supported by the fact
that CXCR2 has the greatest sequence homology with the
recently described human Kaposi’s sarcoma herpes virus-G
protein-coupled receptor (KSHV-GPCR; ORF 74) [36–40].
The KSHV-GPCR demonstrates constitutive activation with
the ability to cause oncogenic transformation of NIH 3T3 cells
and to promote angiogenesis in vivo [36, 40]. Infection of
primary endothelial cells with KSHV and expression of KSHV-
GPCR leads to enhanced proliferation and long-term survival
[38]. The CXC chemokine ligands, IL-8 and GRO-a, can act as
agonists for KSHV-GPCR, and further augment the signaling of
this receptor [41, 42]. It is interesting that introducing a single
point mutation in wild-type CXCR2 and transfection of NIH
3T3 cells results in oncogenic transformation in a similar
manner as KSHV-GPCR [36]. Moreover, wild-type CXCR2
expression in these cells results in cellular transformation
related to autocrine stimulation by an ELR1 CXC chemokine
[36]. However, oncogenic transformation was not induced with
either mutated CXCR1 or wild-type CXCR1 [36]. These data
suggest that either constitutive activation or persistent auto-
crine stimulation of CXCR2 causes cellular transformation
similar to KSHV-GPCR. Thus, the potential expression of
CXCR2 on endothelial cells in the presence of persistent
autocrine (endothelium), juxtacrine (endothelium), and para-
crine (tumor cells or other activated stromal cells) stimulation
with ELR? CXC chemokines has important implications in
promoting angiogenesis. Future studies will delineate whether
CXCR2 is the putative receptor for mediating ELR1 CXC
chemokine angiogenic activity.
Angiostatic (ELR2) CXC chemokines
The angiostatic members of the CXC chemokine family include
PF4, monokine induced by interferon-g (MIG), and interferon-
g-inducible protein (IP-10) [43–48] (Table 1). Although stro-
mal cell-derived factor (SDF-1) is another ELR2 CXC chemo-
kine, it remains unclear whether this ELR2 CXC chemokine
inhibits or promotes angiogenesis. SDF-1 has been found to
induce in vitro migration of human umbilical vein endothelial
cells [49, 50]. Mice with targeted disruption of the SDF-1 gene
perinatally die [51]. This appears to be multi-factorial and
includes defects in B cell and myeloid progenitors, suggesting
that SDF-1 is involved in lymphopoiesis and myelopoiesis. In
addition, these mice demonstrate cardiac ventricular septal
defects [51]. Recently, targeted disruption of the receptor for
SDF-1, CXCR4, has demonstrated that this CXC chemokine
receptor is essential for vascularization of the gastrointestinal
tract, hematopoiesis, and cerebellar development in these mice
[52, 53]. In contrast to these findings, SDF-1 can attenuate the
angiogenic activity of ELR1 CXC chemokines, bFGF, or
VEGF [54]. Thus, the role of SDF-1 in modulating angiogen-
esis in the context of tumorigenesis or chronic fibroproliferative
disorders awaits further study.
All three interferons (IFN-a, -b, and -g) stimulate the
expression of IP-10 [15, 43–48]. MIG is induced only by
IFN-g [15, 43–48]. Recently, a new ELR2 member of the CXC
chemokine family, IFN-inducible T cell alpha chemoattractant
(I-TAC), has been cloned, and is induced primarily by IFN-g
[55]. I-TAC, similar to IP-10 and MIG, inhibits neovascular-
ization in the rat corneal micropocket (CMP) assay of angio-
genesis in response to either ELR1 CXC chemokines or VEGF
(unpublished observation). These findings suggest that all in-
terferon-inducible ELR2 CXC chemokines are potent inhibi-
tors of angiogenesis. Moreover, this interrelationship of inter-
feron and interferon-inducible ELR2 CXC chemokines and
their biological function are directly relevant to the function of
IL-18 and IL-12. The capability of IL-18 and IL-12 to induce
IFN-g and subsequent interferon-inducible ELR2 CXC che-
mokines explains their ability to inhibit angiogenesis [56].
Therefore, IL-12 and IL-18, via the induction of IFN-g, will
have a profound effect on the production of IP-10, MIG, and
TABLE 1. ELR1 and ELR2 CXC Chemokines Are Angiogenic
and Angiostatic Factors, Respectively
Angiogenic CXC chemokines containing the ELR motif (ELR1)
Interleukin-8 (IL-8)
Epithelial neutrophil activating protein-78 (ENA-78)
Growth-related gene alpha (GRO-a)
Growth-related gene beta (GRO-b)
Growth-related gene gamma (GRO-g)
Granulocyte chemotactic protein-2 (GCP-2)
Platelet basic protein (PBP)
Connective tissue activating protein-III (CTAP-III)
Beta-thromboglobulin (b-TG)
Neutrophil activating protein-2 (NAP-2)
Angiostatic CXC chemokines that lack the ELR motif (ELR2)
Platelet factor-4 (PF4)
Interferon-g-inducible protein (IP-10)
Monokine induced by interferon-g (MIG)
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I-TAC. The subsequent expression of interferon-inducible
ELR2 CXC chemokines may represent the final common path-
way and explain the mechanism for the attenuation of angio-
genesis related to interferons. Although all three IFN-inducible
ELR2 CXC chemokines specifically bind to the CXC chemo-
kine receptor, CXCR3 [55, 57], and the expression of CXCR3
mRNA has been associated with endothelial cells [58], it
remains to be determined whether CXCR3 is the putative
receptor for interferon-inducible ELR2 CXC chemokine inhi-
bition of angiogenesis.
Recently, eloquent studies have delineated potential mech-
anisms for the ELR2 CXC chemokine, PF4, and its ability to
inhibit angiogenesis that may be relevant to interferon-induc-
ible ELR2 CXC chemokines. The ability of PF4 to bind to
glycosaminoglycans (GAG; heparin and heparan sulfate) with
high affinity appears to be important to several of its biological
functions. PF4 inhibits endothelial cell migration, prolifera-
tion, and in vivo angiogenesis in response to bFGF or VEGF
[59, 60]. Moreover, fluorescein isothiocyanate (FITC)-labeled
PF4 injected systemically, selectively binds to the endothelium
only in areas of active angiogenesis [61, 62]. This suggests that
the microvasculature is the major target for the biological
effects of PF4 during angiogenesis. PF4 has been shown to
inhibit bFGF and VEGF165 binding to their respective recep-
tors [63–65]. One mechanism for this effect is related to the
generation of PF4-bFGF or PF4-VEGF165 heterodimeric com-
plexes, which impairs bFGF or VEGF165 binding to their
respective receptors [64–66]. bFGF must undergo dimeriza-
tion in the presence of endogenous heparin in order to bind to
its receptor [65, 66]. PF4 complexes to bFGF and prevents
bFGF dimerization followed by impaired receptor binding and
internalization [65]. VEGF165 possesses heparin binding abil-
ity similar to bFGF. PF4 impairs VEGF165 binding to its
receptors on endothelium via a mechanism similar to what has
been reported for its ability to inhibit bFGF [64]. Although the
ability of PF4 to form heterodimers with bFGF and VEGF165 is
one potential mechanism to inhibit bFGF and VEGF165 bio-
logical activity, it appears that PF4 may inhibit angiogenesis
through additional mechanisms.
Although PF4 inhibits specific VEGF165 binding, it does not
inhibit VEGF121 binding to VEGF receptors on endothelial
cells. In contrast to VEGF165, VEGF121 is not a heparin-
binding protein [64, 67, 68]. PF4 neither forms heterodimers
with VEGF121 nor competitively interferes with VEGF121 bind-
ing to its receptor. However, PF4 directly inhibits VEGF121-
induced endothelial cell proliferation [64]. These findings sug-
gest that other mechanisms must be operative for PF4 inhibi-
tion of mitogen stimulation of endothelial cells, perhaps
mediated through its own independent biological signal. Al-
though a specific receptor for PF4 on endothelium has not yet
been discovered, studies have suggested that PF4 inhibits
endothelial cell cycle by preventing cell entry into S phase
[60]. In a model system of endothelial cell stimulation inde-
pendent of interaction with cell-surface GAGs, PF4 inhibits
epidermal growth factor (EGF)-stimulated endothelial cell pro-
liferation by causing a decrease in cyclin E-cyclin-dependent
kinase 2 (cdk2) activity that results in attenuation of retino-
blastoma protein (pRb) phosphorylation [69]. The mechanism
is related to PF4-dependent sustained increase in the levels
and binding of the cyclin-dependent kinase inhibitor (CKI),
p21Cip1/WAF1, to the cyclin E-cdk2 complex. This inhibits
cell cycle progression by preventing the down-regulation of
p21Cip1/WAF1 leading to inhibition of both cyclin E-cdk2 ac-
tivity and phosphorylation of pRb [69]. These studies suggest
that PF4 can inhibit a variety of endothelial cell mitogens at
multiple levels. These events may be relevant to interferon-
inducible ELR2 CXC chemokines because IP-10 has been
shown to compete with PF4 for binding, and inhibition of
endothelial cell proliferation that may be related to inhibition
of the cell cycle [29]. This supports the notion that interferon-
inducible ELR2 CXC chemokines may have similar mecha-
nisms for their inhibition of bFGF, VEGF, EGF, and ELR1
CXC chemokine-induced angiogenesis.
ELR1 CXC chemokines promote angiogenesis
associated with tumorigenesis
The ELR1 CXC chemokines are important mediators of tumor-
igenesis related to their angiogenic properties. Although
GRO-b has been recently reported to inhibit angiogenesis [70],
the concentration used in this study was 1000-fold higher
(1–10 mM) than what was found for its angiogenic activity
(1–10 nM) [23, 54]. This would suggest that superphysiological
concentrations of GRO-b can desensitize the angiogenic re-
sponse. Moreover, studies in melanoma tumors support that all
GROs play a significant role in mediating tumorigenesis re-
lated to both their mitogenic and angiogenic activities. For
example, GRO-a, -b, and -g have all been found to be highly
expressed in human melanoma [71]. To determine the biolog-
ical significance of the presence of these ELR1 CXC chemo-
kines in melanoma, human GRO-a, -b, and -g genes have
been transfected into immortalized murine melanocytes [71,
72]. The persistent expression of GROs in these cells trans-
forms their phenotype to one with anchorage-independent
growth in vitro and the ability to form tumors in vivo in nude
and SCID mice [71, 72]. The tumors are highly vascular and
similar to the vascularity of B16 melanoma controls [71, 72].
When tumors are depleted of GROs there is a marked reduc-
tion of tumor-derived angiogenesis directly related to inhibition
of tumor growth [71, 72]. These findings support the notion that
the ELR1 CXC chemokines, such as GRO-a, -b, and -g, have
the ability to act both as autocrine growth factors for melanoma
and as potent paracrine mediators of angiogenesis to promote
tumorigenesis and metastases.
The progression and growth of ovarian carcinoma is also
dependent on successful angiogenesis, and IL-8 has been
determined to play a significant role in mediating human
ovarian carcinoma-derived angiogenesis and tumorigenesis
[73]. The expression of IL-8, bFGF, and VEGF was examined
in five different human ovarian carcinoma cell lines [73]. All
cell lines in vitro expressed similar levels of bFGF, however,
these cells expressed either high or low levels of IL-8 or VEGF.
When implanted into the peritoneum of nude mice, the high-
expressing IL-8 tumors were associated with all animals dying
in ,51 days [73]. The expression of IL-8 was directly corre-
lated with neovascularization and inversely correlated with
survival, whereas VEGF expression was only correlated with
production of ascites [73]. No correlation was found for bFGF
with either tumor neovascularization or survival [73]. This
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study has been substantiated in patients with ovarian cancer,
where ascites fluid demonstrates angiogenic activity directly
correlated to IL-8 [74]. These findings support the notion that
antigenic ELR1 CXC chemokines play a greater role than
bFGF and VEGF in mediating angiogenesis associated with
ovarian cancer.
IL-8 is markedly elevated and contributes to overall angio-
genic activity of non-small-cell lung cancer (NSCLC) [75].
Extending these studies to an in vivo model system of human
tumorigenesis (i.e., human NSCLC/SCID mouse chimera) [76],
tumor-derived IL-8 was found to be directly correlated with
tumorigenesis [76]. Tumor-bearing animals depleted of IL-8
demonstrated a .40% reduction in tumor growth and a reduc-
tion in spontaneous metastases [76]. The attenuation of tumor
growth and metastases was directly correlated to reduced an-
giogenesis. These findings have been further corroborated
through the use of several human NSCLC cell lines grown in
nude mice. NSCLC cell lines that constitutively express IL-8
display greater tumorigenicity that is directly correlated to
angiogenesis [77].
Although IL-8 was the first angiogenic CXC chemokine to be
discovered in NSCLC, ENA-78 was found to be highly corre-
lated with NSCLC-derived angiogenesis [78]. Surgical speci-
mens of NSCLC tumors demonstrate a direct correlation of
ENA-78 with tumor angiogenesis. These studies were extended
to a SCID mouse model of human NSCLC tumorigenesis.
ENA-78 expression was directly correlated with tumor growth.
Moreover, when NSCLC tumor-bearing animals were depleted
of ENA-78, both tumor growth and spontaneous metastases
were markedly attenuated [78]. The reduction angiogenesis is
also accompanied by an increase in tumor cell apoptosis,
consistent with the previous observation that inhibition of
tumor-derived angiogenesis is associated with increased tumor
cell apoptosis [79, 80]. Similarly, in vivo and in vitro prolifer-
ation of NSCLC cells was unaffected by the presence of ENA-
78. Although a significant correlation of ENA-78 exists with
tumor-derived angiogenesis, tumor growth, and metastases,
ENA-78 depletion does not completely inhibit tumor growth.
This reflects that the angiogenic activity of NSCLC tumors is
related to many overlapping and potentially redundant factors
acting in a parallel or serial manner.
Prostate cancer tumorigenesis and metastasis is dependent
on angiogenesis [81, 82]. Serum levels of IL-8 have been found
to be markedly elevated in patients with prostate cancer. These
levels are highly correlated with the stage of the disease and
have been determined to be an independent variable from the
ratio of free/total prostate specific antigen (PSA) [83]. In fact,
the combined use of free/total PSA and IL-8 levels were more
effective in distinguishing prostate cancer from benign pros-
tatic hypertrophy. This suggests that an ELR1 CXC chemokine
may be playing an important role in mediating prostate cancer-
derived angiogenesis in support of tumorigenesis and metasta-
ses. This observation in patients has been substantiated in
human/SCID mice chimeras of human prostate cancer tumor-
igenesis [84]. Three human prostate cancer cell lines were
examined for constitutive production of angiogenic ELR1 CXC
chemokines [84]. Tumorigenesis of the human prostate cancer
cell line, PC-3, was shown to be attributable, in part, to the
production of the angiogenic CXC chemokine, IL-8. Depletion
of endogenous IL-8 inhibited PC-3 tumor growth in SCID mice,
that was entirely attributable to inhibition of PC-3 tumor-
derived angiogenesis. In contrast, the human prostate cancer
cell line, Du145, was found to utilize a different angiogenic
CXC chemokine, GRO-a, to mediate tumor-derived angiogen-
esis. Depletion of endogenous GRO-a, but not anti-IL-8, re-
duced tumor growth that was directly related to attenuated
angiogenic activity. Thus, prostate cancer cell lines can utilize
distinct CXC chemokines to mediate their tumorigenic poten-
tial. Similar findings have been shown in gastric carcinoma [85,
86]. The findings for the redundancy of ELR1 CXC chemo-
kines in human tumors provides the unique opportunity to
target a putative receptor for ELR1 CXC chemokine-mediated
angiogenesis.
ELR2 CXC chemokines attenuate angiogenesis
associated with tumorigenesis
ELR2 CXC chemokines have been shown to inhibit angiogen-
esis in several model systems. For example, Burkitt’s lym-
phoma cell lines form tumors in nude mice [87]. Angiogenesis
is essential for tumorigenesis of these lymphomas, analogous to
carcinomas. The expression of IP-10 and MIG was found to be
higher in tumors that demonstrated spontaneous regression,
and was directly related to impaired angiogenesis [88]. To
determine whether this effect was attributable to IP-10 or MIG,
more virulent Burkitt’s lymphoma cell lines were grown in
nude mice and subjected to intra-tumor inoculation with either
IP-10 or MIG. Both conditions resulted in marked reduction in
tumor-associated angiogenesis [30, 89]. Although both IP-10
and MIG have been demonstrated to induce mononuclear cell
recruitment via the interaction with their putative CXC che-
mokine receptor (CXCR3) [15–18, 44], the ability of both of
these ELR2 CXC chemokines to inhibit angiogenesis and
induce lymphoma regression in nude mice support that these
chemokines mediate their effects in a T cell-independent man-
ner.
To examine the role of IP-10 in the regulation of angiogen-
esis in a carcinoma, the level of IP-10 from human surgical
NSCLC tumor specimens was examined and found to be sig-
nificantly higher in the tumor specimens than in normal adja-
cent lung tissue [90]. The increase in IP-10 from human
NSCLC tissue was entirely attributable to the higher levels of
IP-10 present in squamous cell carcinoma (SCCA) compared
with adenocarcinoma. Moreover, depletion of IP-10 from SCCA
surgical specimens resulted in augmented angiogenic activity
[90]. The marked difference in the levels and bioactivity of
IP-10 in SCCA and adenocarcinoma is clinically and patho-
physiologically relevant, and represents a possible mechanism
for the biological differences of these two cell types of NSCLC.
Patient survival is lower, metastatic potential is higher, and
evidence of angiogenesis is greater for adenocarcinoma, com-
pared with SCCA of the lung [91–93]. These studies were
extended to a SCID mouse system to examine the effect of
IP-10 on human NSCLC cell line tumor growth in a T- and B
cell-independent manner. SCID mice were inoculated with
either adenocarcinoma or SCCA cell lines [90]. The production
of IP-10 from adenocarcinoma and SCCA tumors was inversely
correlated with tumor growth [90]. However, IP-10 levels were
significantly higher in the SCCA, compared with adenocarci-
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noma tumors. The appearance of spontaneous lung metastases
in SCID mice bearing adenocarcinoma tumors occurred after
IP-10 levels from either the primary tumor or plasma had
reached a nadir. In subsequent experiments, SCID mice bear-
ing SCCA tumors were treated with either neutralizing anti-
IP-10 antibodies, whereas animals bearing adenocarcinoma
tumors were treated with intra-tumor IP-10. Depletion of IP-10
in SCCA tumors resulted in a twofold increase in their size. In
contrast, reconstitution of intra-tumor IP-10 in adenocarci-
noma tumors reduced both their size and metastatic potential,
which was unrelated to infiltrating neutrophils or mononuclear
cells (i.e., macrophages or NK cells) and directly attributable
to a reduction in tumor-associated angiogenesis.
The role of angiogenic (ELR1) and angiostatic
IFN-inducible (ELR2) CXC chemokines in the
regulation of angiogenesis associated with
chronic fibroproliferative disorders
Angiogenesis is increasingly being recognized for its role in
promoting the pathogenesis of chronic inflammatory/fibropro-
liferative disorders. For example, rheumatoid arthritis is asso-
ciated with the unrestrained proliferation of fibroblasts and
capillary blood vessels that leads to the formation of the pannus
and destruction of joint spaces. Macrophages isolated from
rheumatoid synovium produce pro-angiogenic factors [94].
Psoriasis is a well-known angiogenesis-dependent skin disor-
der that is characterized by marked dermal neovascularization.
Keratinocytes isolated from psoriatic plaques demonstrate a
greater production of angiogenic activity. It is interesting that
this angiogenic phenotype is due, in part, to a combined defect
in the overexpression of the angiogenic cytokine IL-8, and a
deficiency in the production of the angiogenesis inhibitor,
thrombospondin-1, resulting in a pro-angiogenic environment
[95].
Idiopathic pulmonary fibrosis (IPF) is a chronic and often
fatal pulmonary fibroproliferative disorder. The pathogenesis of
IPF that ultimately leads to end-stage fibrosis demonstrates
features of dysregulated/abnormal repair with exaggerated neo-
vascularization/vascular remodeling, fibroproliferation, and
deposition of extracellular matrix, leading to progressive fibro-
sis and loss of lung function. Although numerous eloquent
studies have examined the biology of fibroblast proliferation
and deposition of extracellular matrix (ECM) in interstitial lung
disease, few studies have examined the role of angiogenesis/
vascular remodeling that may support fibroplasia and deposi-
tion of ECM in these disorders.
The existence of neovascularization in IPF was originally
identified by Turner-Warwick, who examined the lungs of
patients with widespread interstitial fibrosis and demonstrated
neovascularization leading to anastomoses between the sys-
temic and pulmonary microvasculatures and evidence of ex-
tensive vascular remodeling in areas of fibrosis [96]. These
findings have been further substantiated with evidence of ex-
tensive neovascularization during the pathogenesis of pulmo-
nary fibrosis in bleomycin-induced pulmonary fibrosis [97].
Recently, studies have corroborated the findings of Turner-
Warwick, and have shown that the bronchoalveolar lavage fluid
and lung tissue from patients with IPF have marked angiogenic
activity that is almost entirely attributable to the imbalance in
the overexpression of the angiogenic ELR1 CXC chemokine,
IL-8, compared with the relative down-regulation of the angio-
static IFN-inducible CXC chemokine, IP-10 [98]. To deter-
mine whether the imbalance in the expression of these CXC
chemokines were relevant to the pathogenesis of pulmonary
fibrosis, studies were extended to a murine model system of
bleomycin-induced pulmonary fibrosis. In this model system,
the expression and biological activity of murine macrophage
inflammatory protein-2 (MIP-2; an angiogenic ELR1 CXC
chemokine homologous to human GRO-b/g) and the angiosta-
tic CXC chemokine, IP-10, were correlated to the magnitude of
lung fibrosis during bleomycin-induced pulmonary fibrosis [99,
100]. MIP-2 and IP-10 were measured during bleomycin-
induced pulmonary fibrosis from bronchoalviolar lavage and
whole lung tissue homogenates, and were found to be directly
and inversely correlated, respectively, with total lung hy-
droxyproline levels, a measure of lung collagen deposition [99,
100]. Moreover, if either endogenous MIP-2 was depleted or
exogenous IP-10 (intramuscular) was administered to the ani-
mals during bleomycin exposure, both treatment strategies
resulted in marked attenuation of pulmonary fibrosis that was
entirely attributable to a reduction in angiogenesis in the lung
[99, 100]. These findings support the notion that angiogenesis
is critical to promote fibroplasia and deposition of ECM during
pulmonary fibrosis, and that angiogenic and angiostatic factors,
such as ELR1 and interferon-inducible ELR2 CXC chemo-
kines play an important role in the pathogenesis of this pro-
cess. Furthermore, with the recent demonstration of the effi-
cacy of IFN-g treatment of IPF patients [101, 102], the above
studies substantiate that IFN-g treatment of IPF may mediate
its effect, in part, by shifting the imbalance of the expression of
angiogenic ELR1 and angiostatic interferon-inducible ELR2
CXC chemokines to favor an angiostatic environment leading
to inhibition of dysregulated neovascularization/vascular re-
modeling, fibroproliferation, and deposition of extracellular
matrix in IPF patients.
CONCLUSION
Angiogenesis is regulated by an opposing balance of angiogenic
and angiostatic factors. CXC chemokines are a unique cytokine
family that contains members that exhibit on a structural/func-
tional basis either angiogenic or angiostatic biological activity.
The above studies have demonstrated that, as a family, the CXC
chemokines appear to be important in the regulation of angiogen-
esis associated with both tumorigenesis and the pathogenesis of
chronic inflammatory/fibroproliferative disorders. These findings
support the notion that therapy directed at either inhibition of
angiogenic or augmentation of angiostatic CXC chemokines may
be a novel approach in the treatment of solid tumors and chronic
fibroproliferative disorders.
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